|
|
|
|
|
|
|
15.03.26 - 22:30
|
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate (GlobeNewswire EN)
|
|
|
MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®1, Floretyrosine F 18 or 18F-FET), an investigational PET2 imaging agent for the characterization of recurrent or progressive glioma (brain cancer) from treatment related changes in both adult and pediatric patients....
|
|
|
14.03.26 - 19:33
|
HII′S Ingalls Shipbuilding Celebrates Apprentice School Graduates (GlobeNewswire EN)
|
|
|
PASCAGOULA, Miss., March 14, 2026 (GLOBE NEWSWIRE) -- HII's (NYSE: HII) Ingalls Shipbuilding division celebrated 70 apprentice school graduates during a ceremony at the shipyard today. The event honored the newest class to complete the Department of Labor-registered program, which combines classroom instruction, paid on-the-job training and industry-recognized credentials....
|
|
|
|
|
|
|
|
|
14.03.26 - 09:33
|
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 (GlobeNewswire EN)
|
|
|
SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion,” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Juan Pablo Frías, MD, delivered an oral presentation at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (“ATTD”) in Barcelona on March 14, 2026 highlighting positive 52-week follow-up results from the Company's Phase II COVALENT-111 study evaluating the efficacy, safety, and tolerability of icovamenib in patients with type 2 diabetes (“T2D”)....
|
|
|
|
|
|
|
14.03.26 - 00:09
|
Nobel Announces Change of Transfer Agent (GlobeNewswire EN)
|
|
|
TORONTO, March 13, 2026 (GLOBE NEWSWIRE) -- Nobel Resources Corp. (TSX–V: NBLC; OTCPK: NBTRF) (the “Company” or “Nobel”) announces the appointment of Odyssey Trust Company (“Odyssey”) as the Company's registrar and transfer agent. Odyssey will now be responsible for all transfers of Nobel's shares through their office in Toronto rather than Computershare Investor Services Inc., which has resigned at the Company's request. Shareholders need not take action in respect of the change in transfer agent....
|
|
|
|
|
|
|
|
|
13.03.26 - 22:42
|
Star Equity Holdings to Release Fourth Quarter 2025 Financial Results on March 17 (GlobeNewswire EN)
|
|
|
OLD GREENWICH, Conn., March 13, 2026 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (Nasdaq: STRR and STRRP) ("Star" or the "Company"), formerly Hudson Global, Inc. (Nasdaq: HSON and HSONP), a diversified holding company, announced today that it will release its financial results for the fourth quarter ended December 31, 2025, after the close of the market on Tuesday, March 17, 2026....
|
|
|
|
|
13.03.26 - 22:18
|
Home BancShares, Inc. Announces First Quarter Earnings Release Date and Conference Call (GlobeNewswire EN)
|
|
|
CONWAY, Ark., March 13, 2026 (GLOBE NEWSWIRE) -- Home BancShares, Inc. (NYSE: HOMB), parent company of Centennial Bank, today announced it expects to release First Quarter 2026 earnings after the market closes on April 15, 2026. Following this release, management will conduct a conference call to review these earnings at 1:00 p.m. CT (2:00 p.m. ET) on Thursday, April 16, 2026....
|
|
|
|
|
13.03.26 - 22:03
|
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire EN)
|
|
|
JENA, Germany, March 13, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the “Notice”), dated March 11, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company's ordinary shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”)....
|
|
|
|